Yung Chi Cheng

US Patent:

20080292687, Nov 27, 2008

Filed:

Jun 5, 2006

Appl. No.:

11/921194

Inventors:

Yung Chi Cheng - Woodbridge CT, US

Assignee:

Yale University - New haven CT

International Classification:

A61K 9/127
A61K 31/7072
C07H 7/06
A61P 35/00
A61K 38/20

US Classification:

424450, 514 50, 536 292, 424 852

Abstract:

The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; Rand Rare independently H, an acyl group, a C-Calkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each Ris independently H, or a C-Calkyl or ether group, preferably a C-Calkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.

US Patent:

52781674, Jan 11, 1994

Filed:

May 13, 1992

Appl. No.:

7/882584

Inventors:

Shih H. Chu - Barrington RI
Yung C. Cheng - Woodbridge CT
Bai C. Pan - Providence RI

Assignee:

Brown University Research Foundation - Providence RI

International Classification:

A61K 31505
C07D40112

US Classification:

514269

Abstract:

Novel 6-pyridyl substituted pyrimidine derivatives are disclosed for use as antiviral agents, particularly for the treatment of retroviral infections such as HIV infections and related disorders, as well as for use in anti-cancer therapies to improve the efficacy of anti-cancer therapeutics. These compounds and their pharmacologically acceptable salts operate to disrupt viral replication an exhibit lower cell toxicity, thereby providing more efficient agents for use alone or in conjunction with other chemical or biological agents to provide prolonged antiviral therapy. In addition, the compounds can be used to increase the efficacy of anti-cancer therapeutics including 5-fluropyrimidines such as 5-fluorouracil, thereby reducing the dosage requirement of the therapeutic in anti-cancer therapies so as to decrease toxic effects to the host.